Latest Menorrhagia Stories
BEDFORD, Mass., Nov. 16 /PRNewswire-FirstCall/ -- Hologic, Inc.
NEWPORT, Ky., Nov.
SILVER SPRING, Md., Nov. 13 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
SOUTHAMPTON, England, October 6 /PRNewswire/ -- Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials.
WAYNE, N.J., Oct. 1 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc., announced today that the U.S.
SILVER SPRING, Md., Oct. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention.
BEDFORD, Mass., July 28 /PRNewswire-FirstCall/ -- Hologic, Inc.
Because bleeding from the reproductive tract is a naturally occurring event during menstruation and childbirth, women who exhibit menorrhagia, or excessive bleeding after their menstrual cycle, may have underlying diseases that are underdiagnosed.
Nearly one percent of the population suffers from bleeding disorders, yet many women don't know they have one because doctors aren't looking for the condition, according to researchers at Duke University Medical Center.
Post-Treatment Segment of Elagolix Petal Study Confirms Previous Positive Findings on Efficacy and Safety Neurocrine to Present These Additional Study Results at Deutsche Bank 34th Annual Healthcare Conference Today at 5:05pm Eastern Time SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.